Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients

被引：0
|
作者：
Carlin, Stephanie [1 ]
Gross, Peter L. [2 ,3 ]
机构：
[1] Hamilton Hlth Sci, Hamilton, ON, Canada
[2] McMaster Univ, Hamilton, ON, Canada
[3] McMaster Univ, C5-DBCVSRI, 237 Barton St East, Hamilton, ON L8L 2X2, Canada
来源：
JACC: CARDIOONCOLOGY | 2023年 / 5卷 / 02期
关键词：
cancer-associated thrombosis; real-word cohort;
D O I：
10.1016/j.jaccao.2022.12.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：201 / 202
页数：2
相关论文
共 50 条
  • [31] Rivaroxaban vesus Dalteparin for the Treatment of Cancer-Associated Venous Thromboembolism: the CASTA DIVA Trial
    Meyer, G.
    Girard, P.
    Bertoletti, L.
    Nelson, A. C.
    Laporte, S.
    Mahe, I.
    Sanchez, O.
    Mismetti, P.
    THROMBOSIS RESEARCH, 2021, 200 : S16 - S16
  • [32] Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
    Coleman, Craig, I
    Caroti, Kimberly Snow
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Brobert, Gunnar
    Cohen, Alexander T.
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y.
    Ekbom, Anders
    Carrier, Marc
    BLOOD, 2022, 140 : 11368 - 11369
  • [33] The safety and efficacy of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study)
    Nakamura, M.
    Ishiguro, A.
    Dazai, M.
    Kawamoto, Y.
    Yuki, S.
    Sogabe, S.
    Hosokawa, A.
    Sawada, K.
    Muto, O.
    Umemoto, K.
    Izawa, N.
    Nakashima, K.
    Yagisawa, M.
    Kajiura, S.
    Mitsuhashi, Y.
    Ando, T.
    Sunakawa, Y.
    Kikuchi, Y.
    Yamanaka, T.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S577 - S577
  • [34] Comparison of the Efficacy and Safety of Rivaroxaban and Low Molecular Heparin in Preventing Venous Thromboembolism in Inpatient Cancer Patients
    Wu, Shuyi
    Guan, Chengfu
    Chang, Sijie
    Wang, Chunhua
    Zhang, Jinhua
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (03) : 214 - 222
  • [35] Edoxaban for Cancer-Associated Venous Thromboembolism
    Frere, Corinne
    Dufilho, Monique
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01): : 94 - 94
  • [36] Incidence of cancer-associated venous thromboembolism
    Ballardini, P.
    Zangirolami, A.
    Margutti, G.
    Manfredini, R.
    ANNALS OF ONCOLOGY, 2006, 17 : XI70 - XI71
  • [37] Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: comment
    Di Minno, M. N. D.
    Ageno, W.
    Dentali, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (12) : 2136 - 2138
  • [38] Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: reply
    van der Hulle, T.
    Huisman, M. V.
    Klok, F. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (12) : 2138 - 2139
  • [39] Effectiveness and safety of rivaroxaban versus warfarin for treatment of cancer-associated venous thrombosis
    Coleman, C. I.
    Bunz, T. J.
    Kohn, C. G.
    Beyer-Westendorf, J.
    THROMBOSIS RESEARCH, 2018, 164 : S203 - S203
  • [40] Rivaroxaban treatment of cancer-associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
    Soff, Gerald A.
    Mones, Jodi
    Wilkins, Cy
    Devlin, Sean
    Haegler-Laube, Eva
    Wills, Jonathan
    Sarasohn, Debra M.
    Juluru, Krishna
    Singer, Michael
    Miao, Yimei
    Batista, Jeanette
    Mantha, Simon
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (03) : 349 - 356
12345